It was such a shame that research wasn’t mentioned during the Victoria Derbyshire interview. I had the words ‘Join Dementia Research’ stored at the ready but time just ran out…
Since joining the realms of Twitter I’ve found it a useful source for new research theories – it seems to hold a wealth of information and is the first place you see things. I never thought I’d hear myself say this, but I love it!
Only the other day I saw on the news about the Lancet now declaring that low weight people were more at risk of dementia than overweight………I went onto Twitter to see more. I loved the tweet that said it all really by @ProfJuneAndrews:
‘Being alive in later life associated with increase risk of dementia’
– haha! All that research said to me is what we already know – that more money needs to be spent on research.
It was really encouraging to see the latest research news stating they’d found encouraging research:
New mechanism uncovered in the development of Alzheimer’s disease: is arginine the key?
Obviously it is in its’ very early stages but it highlights to me that they are heading in the right direction. The Alzheimer society were quick to explain the results clearly, which always helps. More can be found at:
Below are some examples of Twitter storing a wealth of information as information comes out about new findings:
Piers Kotting , programme director for NIHR, tweeted about an article in the Telegraph on the 2nd April : ‘A cancer drug that was shelved by AstraZeneca has shown early promise in the treatment of Alzheimer’s Disease’.
Scientists at Yale University have reported that the drug, known as AZD0530, restored memory in mice suffering from the disease.
The findings, published in Annals of Neurology, said the drug worked by blocking a process which breaks the nerve connections used to store memories in the brain. The damage in question is triggered by a harmful plaque known as beta amyloid, which is thought to be one of the leading causes of the debilitating neurological disease.’
Dementiatoday.com is another interesting read – they tweeted:
‘Research on Ginkgo biloba products:
Together with researchers at the Technical University of Berlin (TU Berlin), IQWiG researchers carried out an assessment of Ginkgo-based products. These herbal preparations are made from the leaves of the Ginkgo biloba tree. They are believed to have various benefits, such as improving blood circulation and protecting nerve cells. Ginkgo products are available without a prescription. In Germany, they can also be prescribed by doctors for people who have Alzheimer’s disease.’
On 28th March Adam Smith from Join Dementia Research tweeted a link to the news about aduncanumab in the Daily Mail:
‘The trial shows that aduncanumab significantly reduces amyloid plaque – clumps of protein typically found in the brains of Alzheimer’s patients.
This plaque can lead to the death of nerve cells and loss of brain tissue, causing devastating symptoms such as memory loss and personality changes.
Dr Eric Karran, director of research at Alzheimer’s Research UK, says the drug could prove an effective – and safe – treatment.
He adds: ‘These are very promising early results. It will be important to see results from much larger trials before we can understand how effective this treatment may be.’
Of course, the obvious place to look for new research studies in this country is Join Dementia Research: